A Phase 4 interventional study of Budesonide and Fluticasone in Chronic Obstructive Pulmonary Disease, sponsored by Novartis Pharmaceuticals. Completed at 25 sites in 8 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-04-18.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. Budesonide · Pulmonary Disease, Chronic Obstructive.
Among the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, this one is the 13th largest by enrollment, is one of 4 that started in 2014, is one of 18 in phase 4, and was the 17th registered.
5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →3 of the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
Maria Joyera Rodríguez · Sites in Germany, Netherlands, Spain and 1 more country
Ages 40+
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 222 is above the median of 62 across 3,845 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 99 across the 43 interventional studies. Of the 37 that completed or were terminated, 16 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 43 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
117 studies in Pulmonary Disease, Chronic Obstructive by Novartis: none open now, none under way, none of them phase 3. Of 110 finished, 94 (85%) have results posted.
Among the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis, this one is the 57th largest by enrollment of the 116 interventional ones that give a count, is one of 9 that started in 2014, is one of 24 in phase 4, and was the 96th registered.
Novartis’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2003.
1 of the studies testing budesonide in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 117 in Pulmonary Disease, Chronic Obstructive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To demonstrate the free combination of budesonide and indacaterol is as efficacious as fluticasone and salmeterol in patients with COPD
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a fixed combination of fluticasone and salmeterol during 4 weeks followed by a free combination of budesonide and indacaterol for the remainig of study.
Drug: Budesonide · Drug: Fluticasone · Drug: Indacaterol · Drug: Salmeterol
Fixed combination of fluticasone and salmeterol
Drug: Fluticasone · Drug: Salmeterol
Budesonide 400 mcg twice a day via Breezhaler® device
Fluticasone 250 mcg twice daily via Accuhaler® device
Indacaterol 150 mcg once daily via Breezhaler® device
Salmeterol 50 mcg twice daily via Diskus® device
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (Non-inferiority Analysis).
Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation.
Time frame: Baseline and week 12
Change in Health Status - mMRC
Modified Medical Research Council scale (mMRC) questionnaire will be completed by participants. 0 Not troubled with breathlessness except with strenuous exercise; 1 Troubled by shortness of breath when hurrying on the level or walking up a slight hill; 2 Walks slower than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace on the level; 3 Stops for breath after walking about 100 yards or after a few minutes on the level; 4 Too breathless to leave the house or breathless when dressing or undressing
Time frame: Baseline, week 12 and week 24
Change From Baseline in Mean Daily Number of Puffs of Rescue Medication Used Over the 24 Week Treatment
A day with no rescue medication use is defined from the diary data as any day where the patient recorded no rescue medicine use during the previous 12 hours.
Time frame: 24 weeks
Change From Baseline in Trough Forced Expiratory Volume in 1 Second at Week 24 (Analysis of Superiority)
Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.
Time frame: Baseline and week 24
Change in Health Status - SGRQ-C
St George's Respiratory Questionnaire short version questionnaire will be completed by participants. The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life)
Time frame: Baseline, week 12 and week 24
| Milestone | Budesonide/Indacaterol | Fluticasone / Salmeterol |
|---|---|---|
| Started | 109 | 113 |
| Per-protocol set (pps) | 108 | 111 |
| Completed | 103 | 96 |
| Not completed | 6 | 17 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Non-eligible | 0 | 1 |
| Withdrew: Poor compliance | 1 | 1 |
| Withdrew: Death | 1 | 2 |
| Withdrew: Patient decision | 1 | 1 |
| Withdrew: Use of prohibited treatment | 0 | 3 |
| Withdrew: Ae, study drug would be detrimental | 1 | 3 |
| Withdrew: Withdrawal of informed consent | 1 | 0 |
| Withdrew: Reason unknown | 1 | 5 |
Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation.
| Liters | Budesonide/Indacaterol | Fluticasone / Salmeterol |
|---|---|---|
| Change From Baseline in Trough Forced Expiratory Volume in 1 Second (Non-inferiority Analysis). | 0.080 ± 0.027 | 0.019 ± 0.028 |
Modified Medical Research Council scale (mMRC) questionnaire will be completed by participants. 0 Not troubled with breathlessness except with strenuous exercise; 1 Troubled by shortness of breath when hurrying on the level or walking up a slight hill; 2 Walks slower than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace on the level; 3 Stops for breath after walking about 100 yards or after a few minutes on the level; 4 Too breathless to leave the house or breathless when dressing or undressing
| Score on a scale | Budesonide/Indacaterol | Fluticasone / Salmeterol |
|---|---|---|
| Week 12 | 1.452 ± 0.111 | 1.623 ± 0.113 |
| Week 24 | 1.315 ± 0.112 | 1.414 ± 0.115 |
A day with no rescue medication use is defined from the diary data as any day where the patient recorded no rescue medicine use during the previous 12 hours.
| Puffs | Budesonide/Indacaterol | Fluticasone / Salmeterol |
|---|---|---|
| Change From Baseline in Mean Daily Number of Puffs of Rescue Medication Used Over the 24 Week Treatment | 10.5 ± 9.53 | 12.9 ± 12.34 |
Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.
| Liters | Budesonide/Indacaterol | Fluticasone / Salmeterol |
|---|---|---|
| Change From Baseline in Trough Forced Expiratory Volume in 1 Second at Week 24 (Analysis of Superiority) | 0.063 ± 0.033 | 0.020 ± 0.034 |
St George's Respiratory Questionnaire short version questionnaire will be completed by participants. The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life)
| Score on a scale | Budesonide/Indacaterol | Fluticasone / Salmeterol |
|---|---|---|
| Week 12 | -8.703 ± 2.006 | -2.334 ± 2.053 |
| Week 24 | -7.787 ± 2.308 | -2.523 ± 2.384 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Budesonide / Indacaterol (A) | — | 10/109 (9.2%) | 24/109 (22%) |
| Fluticasone / Salmeterol (B) | — | 9/113 (8%) | 39/113 (34.5%) |
| Event | Budesonide / Indacaterol (A) | Fluticasone / Salmeterol (B) |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 6/109 | 2/113 |
| PneumoniaInfections and infestations | 3/109 | 1/113 |
| Bronchial carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/109 | 0/113 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 1/109 | 0/113 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/109 | 0/113 |
| Acute myocardial infarctionCardiac disorders | 0/109 | 1/113 |
| BradycardiaCardiac disorders | 0/109 | 1/113 |
| Cor pulmonaleCardiac disorders | 0/109 | 1/113 |
| Nodal arrhythmiaCardiac disorders | 0/109 | 1/113 |
| CellulitisInfections and infestations | 0/109 | 1/113 |
| Event | Budesonide / Indacaterol (A) | Fluticasone / Salmeterol (B) |
|---|---|---|
| NasopharyngitisInfections and infestations | 11/109 | 10/113 |
| InfluenzaInfections and infestations | 6/109 | 10/113 |
| HeadacheNervous system disorders | 1/109 | 9/113 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 3/109 | 8/113 |
| Urinary tract infectionInfections and infestations | 3/109 | 7/113 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/109 | 7/113 |
| Back painMusculoskeletal and connective tissue disorders | 1/109 | 6/113 |
| Age, Continuous(Years) | Budesonide/Indacaterol | Fluticasone / Salmeterol | Total |
|---|---|---|---|
| Mean | 67.1 ± 9 | 67.3 ± 8.45 | 67.2 ± 8.70 |
| Sex: Female, Male(Participants) | Budesonide/Indacaterol | Fluticasone / Salmeterol | Total |
|---|---|---|---|
| Female | 41 | 54 | 95 |
| Male | 68 | 59 | 127 |
Ran from May 2014 to primary completion in Jan 2016, 19 months.
Results were first posted in Apr 2017, 1 year 2 months after primary completion.
Of 71 industry-sponsored phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 19 months is above that.
Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Budesonide · Indacaterol
Pulmonary Disease, Chronic Obstructive →